위장관 간질종양의 최신 지견 : 새로운 개념과 치료 New Concepts and Treatment = Recent Advances in Gastrointestinal Stromal Tumors

다국어 초록 (Multilingual Abstract)

The gastrointestinal stromal tumors (GIST) are reevaluated in two points. One is the new concepts of pathogenesis by molecular biological studies and the other is new drug, Glivec, effective for these diseases.
GIST develops through the mutation of KIT protein gene which is transmembrane glycoprotein as functioning of type Ⅲ receptor tyrosine kinase in Cajal cell. Also there are many variations in chromosomes in somewhat constant pattern, which suggest a single clonal origin, such as Cajal cell.
Glivec (imatinib mesylate) is protein tyrosine kinase inhibitor especially In platelet-derived growth factor receptor. It controls GIST with 59% partial remission and minimal side effects less than 5% at the small dosage.
GIST are the new diseases in view of molecular biologic pathogenesis and the promising entity for the new concept anticancer drug of specific targeting the pathogenesis of the cancer in contrast to previous nonspecific targeting drugs.